Combined inhibition of HMGCoA reductase and mitochondrial complex I induces tumor regression of BRAF inhibitor-resistant melanomas

BACKGROUND: Primary and posttreatment resistance to BRAF(V600) mutation–targeting inhibitors leads to disease relapse in a majority of melanoma patients. In many instances, this resistance is promoted by upregulation of mitochondrial oxidative phosphorylation (OxPhos) in melanoma cells. We recently...

Descripción completa

Detalles Bibliográficos
Autores principales: de Groot, Evelyn, Varghese, Sruthy, Tan, Lin, Knighton, Barbara, Sobieski, Mary, Nguyen, Nghi, Park, Yong Sung, Powell, Reid, Lorenzi, Philip L., Zheng, Bin, Stephan, Clifford, Gopal, Y. N. Vashisht
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8862475/
https://www.ncbi.nlm.nih.gov/pubmed/35193687
http://dx.doi.org/10.1186/s40170-022-00281-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8862475/
https://www.ncbi.nlm.nih.gov/pubmed/35193687
http://dx.doi.org/10.1186/s40170-022-00281-0

Ejemplares similares